About Us

---

With over two decades of expertise in Life Sciences business development and sales, Keiji stands as a seasoned professional adept at fostering partnerships between U.S. and Japanese companies. As the visionary behind Amenichi Consulting, LLC, a highly accomplished FDA regulatory consulting firm specializing in facilitating regulatory filings for pharmaceutical and biotechnology companies, Keiji has demonstrated his deep knowledge and proficiency in navigating the complexities of FDA regulations. Moreover, his extensive background spans scientific research, drug development, and venture investing, solidifying his well-rounded understanding of the intricacies involved in the life sciences industry.

With an illustrious career spanning over three decades, Dr. Sugaya is a distinguished authority in the field of Alzheimer's research. As the esteemed professor and head of the Neuroscience department at the University of Central Florida, he plays a pivotal role in advancing scientific understanding and driving innovation in the realm of neurobiology. Furthermore, Dr. Sugaya's influence extends to his position as the chair and CEO of Progenicyte Japan, Inc., the parent company of Progenicyte Therapeutics, Inc. Under his visionary leadership, these organizations are at the forefront of pioneering stem cell therapies for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS. Driven by his passion and commitment, he has authored over 15 influential publications focused on stem cell research, further solidifying his expertise and dedication to improving the lives of those affected by these debilitating conditions.

Christian is a highly accomplished biopharma marketing expert with a strong track record of success. With a keen focus on new product planning strategy and the commercialization of innovative pharmaceutical products, Christian has consistently delivered exceptional results. He has honed his expertise through his tenure at esteemed organizations such as Schering AG, IDEC, Biogen, Medivation, and AstraZeneca, where he has played a pivotal role in driving strategic marketing initiatives on a global scale. Christian's wealth of experience and industry knowledge make him an invaluable asset in navigating the complex landscape of biopharmaceutical marketing.

Scott M. Kahn, Ph.D., is an accomplished leader, team builder, and scientific strategist with extensive industry and academic experience.   Most recently, Dr. Kahn founded Alykomed Global Solutions, LLC, a strategic consultancy firm that provides across the board business development, capital raising, and scientific support for innovative biotech companies.  AGSL also provides targeted partnering, M&A and investment opportunities that align with the strategic interests of large biopharmas and investors/VCs.  Prior, Dr. Kahn held senior executive positions in industry, and before that, Dr. Kahn was a pioneer in personalized medicine research as a two-decade Member, Herbert Irving Comprehensive Cancer Center, Columbia University.  His work formed the foundation for the theory of “Oncogene Addiction”, a widely accepted rationale for the use of targeted therapies in cancer.  Dr. Kahn also co-discovered cyclin D1 amplification in human tumors, and invented novel molecular and cell-based assays that were critical for elucidating the nature of somatic mutations and mutator phenotypes in cancer.  Dr. Kahn serves as founding pro-bono Chairman, Biomarkers Council, for the International Cancer Advocacy Network.